NYSE:GMED Globus Medical - GMED Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Globus Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $53.14 +0.84 (+1.61%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$51.92▼$53.1550-Day Range$51.83▼$79.6352-Week Range$50.92▼$81.78Volume1.24 million shsAverage Volume1.46 million shsMarket Capitalization$5.33 billionP/E Ratio28.57Dividend YieldN/APrice Target$70.91 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Globus Medical MarketRank™ ForecastAnalyst RatingHold2.09 Rating ScoreUpside/Downside33.4% Upside$70.91 Price TargetShort InterestBearish5.02% of Float Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews Sentiment0.75Based on 4 Articles This WeekInsider TradingSelling Shares$2.26 M Sold Last QuarterProj. Earnings Growth10.00%From $2.30 to $2.53 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.06 out of 5 starsMedical Sector30th out of 989 stocksSurgical & Medical Instruments Industry1st out of 99 stocks 4.0 Analyst's Opinion Consensus RatingGlobus Medical has received a consensus rating of Hold. The company's average rating score is 2.09, and is based on 2 buy ratings, 8 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $70.91, Globus Medical has a forecasted upside of 33.4% from its current price of $53.14.Amount of Analyst CoverageGlobus Medical has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.02% of the float of Globus Medical has been sold short.Short Interest Ratio / Days to CoverGlobus Medical has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Globus Medical has recently increased by 50.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGlobus Medical does not currently pay a dividend.Dividend GrowthGlobus Medical does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlobus Medical has received a 57.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Neurostimulators", "Synthetic bone grafts", "Artificial joints", and "Robotic surgery systems" products. See details.Environmental SustainabilityThe Environmental Impact score for Globus Medical is -0.93. Previous Next 3.2 News and Social Media Coverage News SentimentGlobus Medical has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Globus Medical this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for GMED on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat Follows3 people have added Globus Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Globus Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,262,484.00 in company stock.Percentage Held by Insiders24.41% of the stock of Globus Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.23% of the stock of Globus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Globus Medical are expected to grow by 10.00% in the coming year, from $2.30 to $2.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Globus Medical is 28.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.66.Price to Earnings Ratio vs. SectorThe P/E ratio of Globus Medical is 28.57, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 153.24.Price to Earnings Growth RatioGlobus Medical has a PEG Ratio of 1.82. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGlobus Medical has a P/B Ratio of 2.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Globus Medical (NYSE:GMED) StockGlobus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.Read More Receive GMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address GMED Stock News HeadlinesMarch 24, 2023 | americanbankingnews.comGlobus Medical (NYSE:GMED) Downgraded by StockNews.comMarch 21, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Altimmune (ALT) and Globus Medical (GMED)March 25, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 12, 2023 | finance.yahoo.comIs Now The Time To Put Globus Medical (NYSE:GMED) On Your Watchlist?March 2, 2023 | finance.yahoo.comBear of the Day: NuVasive (NUVA)February 23, 2023 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on Globus Medical (GMED)February 23, 2023 | finance.yahoo.comGlobus Medical, Inc. (NYSE:GMED) Q4 2022 Earnings Call TranscriptFebruary 23, 2023 | finance.yahoo.comGlobus Medical Full Year 2022 Earnings: EPS Misses ExpectationsMarch 25, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. February 21, 2023 | fool.comGlobus Medical (GMED) Q4 2022 Earnings Call TranscriptFebruary 21, 2023 | finance.yahoo.comGlobus Medical Reports Fourth Quarter and Full Year 2022 ResultsFebruary 21, 2023 | finance.yahoo.comGlobus Medical (GMED) Tops Q4 Earnings EstimatesFebruary 20, 2023 | benzinga.comGlobus Medical Earnings PreviewFebruary 12, 2023 | seekingalpha.comGlobus Medical: Back PainsFebruary 11, 2023 | benzinga.comLifshitz Law PLLC Announces Investigations of SUMO, GMED, NUVA, and CSIIFebruary 11, 2023 | msn.com6 Analysts Have This to Say About Globus MedicalFebruary 10, 2023 | msn.comGlobus Medical slide continues after a raft of downgrades after NuVasive dealFebruary 10, 2023 | reuters.comGlobus Medical's $3 bln deal for NuVasive to fortify spinal business spooks investorsFebruary 10, 2023 | finance.yahoo.comGlobus Medical (NYSE:GMED) Is Reinvesting At Lower Rates Of ReturnFebruary 9, 2023 | msn.comGMED Tanks on NuVasive DealFebruary 9, 2023 | barrons.comS&P 500 Futures Climb in Premarket Trading; Globus Medical, Mattel LagFebruary 9, 2023 | in.investing.comGlobus Medical and NuVasive announce merger agreementFebruary 9, 2023 | msn.comGlobus Medical and NuVasive to combine in an all-stock dealFebruary 3, 2023 | finance.yahoo.comStrength Seen in Nevro (NVRO): Can Its 5.1% Jump Turn into More Strength?February 2, 2023 | finance.yahoo.comGlobus Medical Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference CallJanuary 16, 2023 | finance.yahoo.comHere's Why Investors Should Retain Globus Medical (GMED) StockJanuary 14, 2023 | finance.yahoo.com15 Largest Orthopedic Companies in the WorldSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address GMED Company Calendar Last Earnings2/21/2023Today3/24/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:GMED CUSIP37957720 CIK1237831 Webwww.globusmedical.com Phone(610) 930-1800Fax610-930-2042Employees2,600Year FoundedN/APrice Target and Rating Average Stock Price Forecast$70.91 High Stock Price Forecast$78.00 Low Stock Price Forecast$61.00 Forecasted Upside/Downside+33.4%Consensus RatingHold Rating Score (0-4)2.09 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$1.86 Trailing P/E Ratio28.57 Forward P/E Ratio23.10 P/E Growth1.82Net Income$190.17 million Net Margins18.59% Pretax Margin23.76% Return on Equity11.93% Return on Assets10.62% Debt Debt-to-Equity RatioN/A Current Ratio6.18 Quick Ratio4.30 Sales & Book Value Annual Sales$759.12 million Price / Sales7.02 Cash Flow$2.84 per share Price / Cash Flow18.68 Book Value$18.43 per share Price / Book2.88Miscellaneous Outstanding Shares100,300,000Free Float75,818,000Market Cap$5.33 billion OptionableOptionable Beta1.05 Key ExecutivesDaniel T. ScavillaPresident, Chief Executive Officer & DirectorKeith W. PfeilCFO, Chief Accounting Officer & Senior VPKelly G. HullerSecretary, Senior VP & General CounselBrian KearnsSenior Vice President-Business DevelopmentKey CompetitorsIntegra LifeSciencesNASDAQ:IARTNuVasiveNASDAQ:NUVAAtriCureNASDAQ:ATRCAlphatecNASDAQ:ATECTeleflexNYSE:TFXView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 751 shares on 3/23/2023Ownership: 0.049%Voya Investment Management LLCSold 15,557 shares on 2/28/2023Ownership: 0.136%NatixisSold 5,911 shares on 2/24/2023Ownership: 0.100%Teachers Retirement System of The State of KentuckyBought 2,093 shares on 2/22/2023Ownership: 0.044%Northwestern Mutual Investment Management Company LLCSold 3,962 shares on 2/21/2023Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions GMED Stock - Frequently Asked Questions Should I buy or sell Globus Medical stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMED, but not buy additional shares or sell existing shares. View GMED analyst ratings or view top-rated stocks. What is Globus Medical's stock price forecast for 2023? 11 Wall Street analysts have issued 12-month target prices for Globus Medical's stock. Their GMED share price forecasts range from $61.00 to $78.00. On average, they predict the company's share price to reach $70.91 in the next year. This suggests a possible upside of 33.4% from the stock's current price. View analysts price targets for GMED or view top-rated stocks among Wall Street analysts. How have GMED shares performed in 2023? Globus Medical's stock was trading at $74.27 at the beginning of the year. Since then, GMED shares have decreased by 28.5% and is now trading at $53.14. View the best growth stocks for 2023 here. Are investors shorting Globus Medical? Globus Medical saw a increase in short interest in February. As of February 28th, there was short interest totaling 3,870,000 shares, an increase of 50.0% from the February 13th total of 2,580,000 shares. Based on an average daily trading volume, of 1,130,000 shares, the short-interest ratio is currently 3.4 days. Currently, 5.0% of the shares of the stock are sold short. View Globus Medical's Short Interest. When is Globus Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our GMED earnings forecast. How were Globus Medical's earnings last quarter? Globus Medical, Inc. (NYSE:GMED) issued its quarterly earnings data on Tuesday, February, 21st. The medical device company reported $0.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. The medical device company had revenue of $274.50 million for the quarter, compared to analyst estimates of $276.40 million. Globus Medical had a net margin of 18.59% and a trailing twelve-month return on equity of 11.93%. The business's revenue for the quarter was up 9.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.49 EPS. What ETFs hold Globus Medical's stock? ETFs with the largest weight of Globus Medical (NYSE:GMED) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust Indxx Medical Devices ETF (MDEV), SPDR S&P Health Care Equipment ETF (XHE), First Trust Health Care AlphaDEX Fund (FXH), First Trust Innovation Leaders ETF (ILDR) and ROBO Global Robotics & Automation ETF (ROBO). What guidance has Globus Medical issued on next quarter's earnings? Globus Medical issued an update on its FY 2023 earnings guidance on Tuesday, February, 21st. The company provided earnings per share guidance of $2.30-$2.30 for the period, compared to the consensus estimate of $2.34. The company issued revenue guidance of $1.10 billion-$1.10 billion, compared to the consensus revenue estimate of $1.12 billion. What is David Demski's approval rating as Globus Medical's CEO? 47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com. David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Globus Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA). What is Globus Medical's stock symbol? Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED." Who are Globus Medical's major shareholders? Globus Medical's stock is owned by many different retail and institutional investors. Top institutional investors include William Blair Investment Management LLC (2.32%), GW&K Investment Management LLC (1.71%), Geneva Capital Management LLC (1.43%), JPMorgan Chase & Co. (1.34%), Geode Capital Management LLC (1.20%) and Wells Fargo & Company MN (1.19%). Insiders that own company stock include Daniel T Scavilla, Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, James R Tobin, Keith W Pfeil, Keith W Pfeil, Kelly Huller and Robert Andrew Douglas. View institutional ownership trends. How do I buy shares of Globus Medical? Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Globus Medical's stock price today? One share of GMED stock can currently be purchased for approximately $53.14. How much money does Globus Medical make? Globus Medical (NYSE:GMED) has a market capitalization of $5.33 billion and generates $759.12 million in revenue each year. The medical device company earns $190.17 million in net income (profit) each year or $1.86 on an earnings per share basis. How many employees does Globus Medical have? The company employs 2,600 workers across the globe. How can I contact Globus Medical? Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The official website for the company is www.globusmedical.com. The medical device company can be reached via phone at (610) 930-1800, via email at investors@globusmedical.com, or via fax at 610-930-2042. This page (NYSE:GMED) was last updated on 3/25/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.